Immunovant is a clinical-stage immunology company developing IMVT-1402, a fully human monoclonal antibody that inhibits the neonatal Fc receptor (FcRn) to reduce disease-driving IgG antibodies. The stock carries a "Buy" consensus across roughly 17 analysts, and the arithmetic mean of recent verified price targets is approximately $49, with individual targets spanning from about $30 to $66.
Views are unusually wide because analysts are pricing different outcomes for a pre-revenue pipeline. On the bullish side, Bank of America (Dina Ramadane) and Wells Fargo (Derek Archila) both carry $45 targets, JPMorgan holds an Overweight rating with a $50 target, LifeSci Capital (Sam Slutsky) sits at $53, Oppenheimer at $54, Citi near $57, and Piper Sandler at the high end near $66. Cautious voices include Bernstein at $37, Goldman Sachs at $32, and Truist Financial at about $30, reflecting skepticism about whether the pivotal programs will succeed. The dispersion means the $49 central target should be read as a probability-weighted midpoint, not a guarantee.
At roughly $35, shares would need to appreciate close to 40% to reach $49, a very large move. The stock trades within a 52-week range of about $21 to $45, so $49 sits above the prior high and would require a new all-time-high break. Reaching it likely depends on positive pivotal data rather than gradual re-rating, because Immunovant has no product revenue and is valued almost entirely on IMVT-1402.
In its fiscal second quarter reported in early November, the company posted a narrower-than-expected loss and announced that IMVT-1402 600 mg met the primary endpoint (ACR20 at Week 28) in a potentially registrational difficult-to-treat rheumatoid arthritis (D2T RA) trial. However, the 300 mg dose did not separate from placebo and secondary endpoints missed statistical significance, leaving the regulatory path undefined pending FDA discussions.
The FcRn mechanism is clinically validated by commercial drugs such as argenx's Vyvgart and UCB's Rystiggo in myasthenia gravis. IMVT-1402 is designed to deliver deep IgG reduction while minimizing the LDL cholesterol and albumin effects that troubled Immunovant's earlier candidate, batoclimab. The company held roughly $722 million in cash as of September 30, 2026, enough to fund operations toward a potential Graves' disease launch, and management reports strong enrollment in Graves' disease studies with pivotal readouts expected in 2027. A clean safety profile and positive analyst revisions following the RA data support the bullish case.
The 300 mg dose's failure and missed secondary endpoints raise questions about whether the 600 mg signal will replicate in Phase 3. The pipeline has narrowed: a cutaneous lupus proof-of-concept study missed its primary endpoint, and management now views further Sjögren's development as unlikely beyond the ongoing Phase 2 trial. With no revenue and a net loss of roughly $97 million in the latest quarter, the company remains dependent on cash reserves and future financing. Binary 2027 readouts, competitive FcRn programs, and potential regulatory hurdles all represent meaningful downside risks.
The 52-week range of roughly $21 to $45 is the key structural reference. The prior high near $45 acts as major resistance, and $49 would represent a breakout into uncharted territory. The round-number $30 level has served as a notable floor during 2026, while the post-earnings jump toward $35 has placed shares in the middle of the range. A sustained move above $45 would be the first meaningful technical confirmation of a path toward the analyst-derived target.
Analyst price targets typically reflect a roughly 12-month research horizon, though no single uniform date applies across firms. The most consequential catalysts are the pivotal Graves' disease and myasthenia gravis data expected in 2027, the FDA discussions on the D2T RA registration path, and any further pipeline or financing updates. Investors should watch analyst target revisions, cash burn, and enrollment updates, as well as an investor day scheduled for December 2026.
Tickeron's AI Daily Buy/Sell Signals use artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a volatile, data-driven name like Immunovant, these signals can help traders discover opportunities, monitor positions, and spot shifting trends more efficiently than manual review. Traders interested in a systematic edge can explore the signals to complement their own research.
Whether Immunovant can reach $49 hinges less on near-term earnings and more on whether IMVT-1402 delivers pivotal success in Graves' disease and myasthenia gravis. The roughly 40% required move is substantial, the analyst range of $30 to $66 is unusually wide, and the bulls and bears disagree sharply on the pipeline's probability-adjusted value. A clean safety profile, validated mechanism, and cash runway support the optimistic case, while dose-response uncertainty, a narrowed pipeline, and regulatory ambiguity are the principal obstacles. Investors should focus on the 2027 data readouts and any FDA guidance on the RA program rather than on any single target figure.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
A.I.dvisor indicates that over the last year, IMVT has been loosely correlated with ROIV. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if IMVT jumps, then ROIV could also see price increases.
| Ticker / NAME | Correlation To IMVT | 1D Price Change % | ||
|---|---|---|---|---|
| IMVT | 100% | +7.54% | ||
| ROIV - IMVT | 64% Loosely correlated | +6.17% | ||
| LXEO - IMVT | 50% Loosely correlated | -0.52% | ||
| KURA - IMVT | 48% Loosely correlated | +6.91% | ||
| XNCR - IMVT | 47% Loosely correlated | +4.99% | ||
| SYRE - IMVT | 46% Loosely correlated | +7.53% | ||
More | ||||